# A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers

> **NCT06348355** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 7 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** [11C]savolitinib
- **DRUG:** Savolitinib

## Key facts

- **NCT ID:** NCT06348355
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-12
- **Primary completion:** 2024-06-24
- **Final completion:** 2024-06-24
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06348355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06348355, "A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06348355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*